FDA to Ban JUUL E-Cigarettes Over Youth Appeal

Jun.24.2022
The FDA prohibits JUUL e-cigarettes due to concerns about their impact on youth vaping. Nicotine is highly addictive and dangerous for teens.

The US Food and Drug Administration (FDA) announced today that it will ban the sale of JUUL e-cigarettes, citing the company's significant role in the popularity of youth e-cigarette use. Critics argue that JUUL's aggressive marketing tactics have led more teenagers to take up vaping. Public health experts warn that e-cigarettes are unsafe for youth, children, and young adults, as they contain nicotine, a highly addictive substance. Studies have also shown that exposure to nicotine during adolescence can lead to persistent behavioral problems, higher anxiety rates, and impulse control issues.

 

According to Adnan Hyder, Director of the Health and Business Decision-making Center at George Washington University and Senior Associate Dean for Public Health at the GW Milken Institute School of Public Health, the e-cigarette industry is taking advantage of the vulnerability of young people and exposing them to health risks. Hyder observed that the industry is using tactics commonly used by the tobacco industry, such as attacking regulations, promoting controversial evidence, promoting distrust, and utilizing marketing strategies like social media and advertising. He welcomed the FDA's decision and hopes that more regulations and restrictions on nicotine and tobacco products will follow.

 

Nino Paichadze, the Deputy Director and Expert on Health Business Determinants at the center states: "Electronic cigarettes are a rapidly emerging and diversified product category, particularly appealing to young adults and teens. As of 2021, over two million American middle and high school students reported currently using e-cigarettes. JUUL is just one of many e-cigarettes that contain high levels of nicotine, which is harmful to the developing brains of teens and can lead to numerous adverse health conditions. The company has been strategically marketing their products, taking advantage of the innocence and independence of young people. Given that young adults and teens are a crucial stage in human development, and considering the alarming statistics on e-cigarette use among American youth, the FDA's decision is both timely and necessary. This is a major victory for public health today!

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
Why Many E-Liquids Today Are "Not Bad, but Not Memorable" – Mylor’s Approach to Experience Design
From May 8 to 10, 2026, Mylor (Booth E70) will exhibit at The Vaper Expo UK, where it will showcase its systematic experience design solutions for e-liquids. At present, the e-liquid market commonly faces a challenge: many products have “no obvious shortcomings, but lack memorable features.” In response, Mylor has proposed refined solutions across multiple dimensions, including device-adaptive sweetness, progressive cooling sensation, fruit-oriented sourness, and segmented nicotine experience.
May.08
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai
Japan to Raise Tobacco Taxes and Corporate Income Tax From April 1 to Help Fund Defense Spending
Japan to Raise Tobacco Taxes and Corporate Income Tax From April 1 to Help Fund Defense Spending
Japan will raise tobacco product taxes and corporate income tax from April 1 as part of a package of levies to help fund a five-year defense spending increase totaling JPY 43 trillion. Tobacco taxes will be raised in two stages, with the first increase taking effect on April 1 and the second in October, while personal income tax is planned to rise in January.
Mar.27 by 2FIRSTS.ai
Can hookah go institutional? A hookah company seeking to go public makes its case with capital, technology and regulation
Can hookah go institutional? A hookah company seeking to go public makes its case with capital, technology and regulation
2Firsts explored whether hookah can evolve into a more mature and governable category by interviewing Dubai-based hookah company AIR. AIR argues that strong margins, OOKA’s closed-system model and the prospect of differentiated regulation could support that shift. The larger question is whether this is simply AIR’s capital-markets narrative, or an early sign that competition, regulation and category boundaries in hookah are beginning to change.
Apr.02
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
Fifth Circuit Hears Challenge to FDA’s Standard for Reviewing Flavored Vape Applications
A three-judge panel of the U.S. Court of Appeals for the Fifth Circuit heard oral arguments on Tuesday in a case brought by seven small vape-liquid companies challenging the Food and Drug Administration’s denial of marketing authorization for their flavored electronic nicotine products.
Apr.30 by 2FIRSTS.ai
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai